Ace investor Dolly Khanna has exited Sharda Cropchem Ltd., according to the June 2026 shareholding pattern. She held a 1.09% stake in the company at the end of March 2026, but her name no longer appears among shareholders holding more than 1% in the June quarter, indicating that she has either completely exited or reduced her stake below the disclosure threshold.
While the exit of a well-known investor often attracts market attention, brokerage firm Anand Rathi believes the company’s fundamentals remain compelling and sees significant upside from current levels.
Brokerage Maintains Bullish View
In its research report dated 30 July 2026, Anand Rathi has maintained a positive stance on Sharda Cropchem with a target price of ₹1,350, implying an upside potential of around 64%.
The brokerage expects the company’s earnings momentum to continue, supported by improving business fundamentals and an expected recovery in demand.
Volume Revival to Drive Growth
According to the report, Sharda Cropchem is witnessing encouraging signs of a recovery in volumes across key markets. After a challenging period for the global agrochemical industry marked by inventory corrections and weak pricing, the operating environment is gradually improving.
The brokerage believes that this revival in volumes should sustain the company’s earnings growth over the coming years.
Attractive Valuation Despite Improving Outlook
One of the key reasons behind Anand Rathi’s positive view is the company’s inexpensive valuation.
The stock is currently trading at only around 11x FY27 estimated earnings and 10x FY28 estimated earnings, levels that the brokerage considers attractive given the improving earnings trajectory and healthy return profile.
For investors looking at reasonably valued businesses with improving fundamentals, Sharda Cropchem stands out as an interesting opportunity.
Debt-Free Balance Sheet Provides Comfort
Sharda Cropchem also enjoys a very strong financial position.
The company has a net cash balance exceeding ₹7.5 billion, giving it significant financial flexibility. A cash-rich balance sheet enables the company to comfortably fund growth initiatives, navigate industry cycles, and create long-term shareholder value without relying heavily on debt.
Such financial strength also reduces downside risks during periods of market uncertainty.
Healthy Profitability Metrics
Apart from balance-sheet strength, the company continues to generate impressive returns on capital.
According to the brokerage estimates, Sharda Cropchem is expected to deliver approximately:
- Return on Equity (RoE): 25%
- Return on Capital Employed (RoCE): 30%
These are among the strongest profitability ratios in the sector and reflect efficient capital allocation and a high-quality business model.
Does Dolly Khanna’s Exit Change the Story?
The exit of a marquee investor often leads to questions about the investment thesis. However, investors should remember that individual portfolio decisions can be driven by several factors, including profit booking, portfolio rebalancing, liquidity requirements, or changing allocation preferences.
Such moves do not necessarily indicate deterioration in a company’s underlying fundamentals.
In fact, Anand Rathi’s latest research suggests that the company’s business outlook remains constructive, with improving demand, attractive valuations, robust cash reserves, and healthy return ratios supporting future earnings growth.
The Bottom Line
Sharda Cropchem appears to be entering a phase where business fundamentals are improving after an extended industry slowdown. With volume recovery gaining traction, a debt-free balance sheet carrying more than ₹7.5 billion in net cash, strong profitability metrics, and a valuation of just 10–11 times forward earnings, the stock offers an interesting risk-reward profile.
While Dolly Khanna’s exit is likely to draw attention, long-term investors may find it worthwhile to focus on the company’s operational performance and earnings outlook rather than solely on changes in shareholding. If Anand Rathi’s projections play out, Sharda Cropchem could offer meaningful upside over the medium term.
